Noticias y Actividades de PureTech

PureTech es una de las ...

• FTSE SmallCaps.

PureTech es una empresa que cotiza bajo el símbolo de cotización PRTC (US).

Ver el organigrama con sus 49 ejecutivos principales

Biografías más buscadas en PureTech

• Robert Lyne, Chief Executive Officer
• Sharon Barber-Lui, Interim Chairman of the Board
• Robert Langer, Non Executive Director and Chair Research and Devel...

Recientes movimientos de ejecutivos en PureTech

• Robert Lyne que ha sido Interim Chief Executive Officer, ha ascendido a Chief Executive Officer  (noticia publicada el 18 de diciembre de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en PureTech.

PureTech tiene 2.405 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).

Popular M&A news in Biotecnología

• IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
• NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado el 1 de junio de 2026)..

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Valerie Hanote - Non-Executive Director en Eurofins

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de PureTech

• Notice of Half-Yearly Results | PureTech Health
• PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan | PureTech Health
• PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate | PureTech Health
• PureTech Founded Entity Akili Announces Public Company Board of Director Nominees | PureTech Health
• PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb) | PureTech Health
• PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia | PureTech Health
• PureTech News | PureTech Health
• PureTech Founded Entity Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million | PureTech Health
• Results of Annual General Meeting | PureTech Health
• PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications | PureTech Health
• View more press releases Close

Redes sociales sobre PureTech

• PureTech en Wikipedia, Google News y Yahoo Finance
• PureTech en LinkedIn, Twitter y YouTube